Acerus Announces Definitive Agreement To Acquire Serenity Llc And The Global Rights To Noctiva™
Acquiring Company
Acerus
Acquired Company
Rights
DenverBiotechnologySoftwareHealth Careinformation technology & servicesDescription
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a definitive agreement (the “Definitive Agreement”) to indirectly acquire Serenity LLC (“Serenity”) and the global rights to its Noctiva brand in a combined cash and stock transaction. Serenity, based in Miami, FL, is a specialty pharmaceutical company, focused on developing therapies for diseases associated with voiding disorders, and had previously been granted approval by the U.S. Food and Drug Administration (FDA) for its Noctiva (desmopressin acetate) nasal spray. Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1 It is the first FDA-approved therapy for nocturia.
Quick answer
Acerus is acquiring Rights and Serenity, announced February 28, 2022.
- How much did Acerus pay for Rights?
- The deal value was not disclosed.
- What does Acerus do?
- Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the..
Source: Fundz verified event record.
Other recent acquisitions in information technology & services and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Halozyme To Acquire Antares Pharma To Create A Specialty Product And Drug Delivery Leader (April 13, 2022)
- Masimo Closes Acquisition Of Sound United (April 12, 2022)
- Acerus Announces Closing Of Acquisition Of Serenity Pharmaceuticals Llc And Acquisition Of Global Rights To Noctiva™ (March 7, 2022)
- Health Catalyst Announces Intent To Acquire Kpi Ninja (February 22, 2022)
- Element Biosciences Closes Acquisition Of Loop Genomics (February 8, 2022)
- Intellia Therapeutics Announces Acquisition Of Rewrite Therapeutics (February 3, 2022)
Who to call at Acerus, and when
When Acerus changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Acerus raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Acerus, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Acerus. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Acerus makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Rights?
Rights was acquired by Acerus. The deal was reported on February 28, 2022. Acerus is privately held.
When did Acerus acquire Rights?
Acerus's acquisition of Rights was reported on February 28, 2022. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Rights do?
Audio interviews about Rights Management It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.